Status:
UNKNOWN
Xenon Inhalation for Treatment of Panic Disorder
Lead Sponsor:
Nobilis Therapeutics Inc.
Conditions:
Panic Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with panic disorder.
Eligibility Criteria
Inclusion
- Primary diagnosis of panic disorder according to DSM-5.
- Male and female patients ≥18 years of age.
Exclusion
- History of schizophrenia, bipolar and other psychotic disorders.
- Patients with underlying pulmonary disease, chronic obstructive pulmonary disease (COPD), asthma, severe lung disease and/or baseline oxygen saturations \<92% or any other respiratory conditions / diseases that may affect the respiratory function.
- Currently undergoing targeted empirically-driven psychotherapy for panic disorder or panic disorder-related symptoms.
- Currently undergoing exposure-based psychotherapy for any condition.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04432155
Start Date
June 1 2021
End Date
December 1 2021
Last Update
March 3 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.